Jefferies Group Comments on Bayer AG’s FY2017 Earnings (BAYRY)
Bayer AG (OTCMKTS:BAYRY) – Equities researchers at Jefferies Group lowered their FY2017 earnings per share (EPS) estimates for Bayer AG in a research report issued on Tuesday. Jefferies Group analyst J. Holford now anticipates that the company will post earnings per share of $1.86 for the year, down from their prior forecast of $2.23. Jefferies Group also issued estimates for Bayer AG’s FY2018 earnings at $2.11 EPS and FY2019 earnings at $2.29 EPS.
Several other research analysts also recently commented on the stock. Zacks Investment Research raised shares of Bayer AG from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. BNP Paribas raised shares of Bayer AG from a “neutral” rating to an “outperform” rating in a research note on Monday, September 25th. Finally, ValuEngine downgraded shares of Bayer AG from a “buy” rating to a “hold” rating in a research report on Friday, September 22nd. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $148.00.
Bayer AG (OTCMKTS BAYRY) traded down $0.01 during mid-day trading on Friday, reaching $31.79. 244,323 shares of the company traded hands, compared to its average volume of 518,443. The stock has a market cap of $104,760.00, a P/E ratio of 15.91, a PEG ratio of 2.38 and a beta of 1.15. Bayer AG has a 52 week low of $22.88 and a 52 week high of $35.41. The company has a quick ratio of 1.29, a current ratio of 1.74 and a debt-to-equity ratio of 0.40.
Bayer AG Company Profile
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.